Details of the Drug

General Information of Drug (ID: DM6L5VO)

• Drug Name: Methsuximide
• Synonyms: Celontin; Mesuximid; Mesuximida; Mesuximide; Mesuximidum; Methsuximid; Metosuccimmide; Metsuccimide; Petinutin; Methsuximide [BAN]; Metosuccimmide [DCIT]; PM 396; Alpha-Methylphensuximide; Celontin (TN); Mesuximida [INN-Spanish]; Mesuximide (INN); Mesuximidum [INN-Latin]; Methsuximide (USP); Petinutin (TN); Alpha-Methyl-alpha-phenyl N-methyl succinimide; N,2-Dimethyl-2-phenylsuccinimide; N-Methyl-alpha-methyl-alpha-phenylsuccinimide; (+-)-N,2-Dimethyl-2-phenylsuccinimide; (RS)-1,3-Dimethyl-3-phenyl-2,5-pyrrolidindion; 1,3-Dimethyl-3-phenyl-2,5-dioxopyrrolidine; 1,3-Dimethyl-3-phenyl-2,5-pyrrolidinedione; 1,3-Dimethyl-3-phenyl-pyrrolidin-2,5-dione; 1,3-Dimethyl-3-phenylsuccinimide; 1,3-dimethyl-3-phenylpyrrolidine-2,5-dione

Indication

Disease Entry	ICD 11	Status	REF
Absence epilepsy	N.A.	Approved	[1]
Epilepsy	8A60-8A68	Approved	[1]
Epileptic seizures	8A61-8A6Z	Approved	[2]

• Therapeutic Class: Anticonvulsants
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 203.24
  Logarithm of the Partition Coefficient (xlogp); 1.2
  Rotatable Bond Count (rotbonds); 1
  Hydrogen Bond Donor Count (hbonddonor); 0
  Hydrogen Bond Acceptor Count (hbondacc); 2
• ADMET Property: Half-life: The concentration or amount of drug in body reduced by one-half in 1.4 - 2.6 hours [3]
• Chemical Identifiers:
  Formula: C12H13NO2
  IUPAC Name: 1,3-dimethyl-3-phenylpyrrolidine-2,5-dione
  Canonical SMILES: CC1(CC(=O)N(C1=O)C)C2=CC=CC=C2
  InChI: InChI=1S/C12H13NO2/c1-12(9-6-4-3-5-7-9)8-10(14)13(2)11(12)15/h3-7H,8H2,1-2H3
  InChIKey: AJXPJJZHWIXJCJ-UHFFFAOYSA-N
• Cross-matching ID:
  PubChem CID: 6476
  ChEBI ID: CHEBI:6846
  CAS Number: 77-41-8
  DrugBank ID: DB05246
  TTD ID: D08EOD
  INTEDE ID: DR1050
  ACDINA ID: D00415
• Repurposed Drugs (RPD): Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Voltage-gated calcium channel alpha Cav3.1 (CACNA1G)	TT729IR	CAC1G_HUMAN	Blocker	[4]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Mephenytoin 4-hydroxylase (CYP2C19) Main DME	DEGTFWK	CP2CJ_HUMAN	Substrate	[5]

Molecular Expression Atlas of This Drug

• The Studied Disease: Absence epilepsy

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Voltage-gated calcium channel alpha Cav3.1 (CACNA1G)	DTT	CACNA1G	3.88E-01	-0.06	-0.18
Voltage-gated calcium channel alpha Cav3.1 (CACNA1G)	DTT	CACNA1G	9.84E-01	-0.01	-0.03
Mephenytoin 4-hydroxylase (CYP2C19)	DME	CYP2C19	7.39E-01	1.54E-02	4.74E-02
Mephenytoin 4-hydroxylase (CYP2C19)	DME	CYP2C19	4.64E-02	-8.21E-02	-7.11E-01

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Methsuximide (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Levomilnacipran	DMV26S8	Moderate	Antagonize the effect of Methsuximide when combined with Levomilnacipran.	Chronic pain [MG30]	[6]
Vilazodone	DM4LECQ	Moderate	Antagonize the effect of Methsuximide when combined with Vilazodone.	Depression [6A70-6A7Z]	[6]
Vortioxetine	DM6F1PU	Moderate	Antagonize the effect of Methsuximide when combined with Vortioxetine.	Depression [6A70-6A7Z]	[6]
Desvenlafaxine	DMHD4PE	Moderate	Antagonize the effect of Methsuximide when combined with Desvenlafaxine.	Depression [6A70-6A7Z]	[6]
Esketamine	DMVU687	Moderate	Additive CNS depression effects by the combination of Methsuximide and Esketamine.	Depression [6A70-6A7Z]	[7]
Allopregnanolone	DMNLHAC	Moderate	Additive CNS depression effects by the combination of Methsuximide and Allopregnanolone.	Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z]	[8]
Lasmiditan	DMXLVDT	Moderate	Additive CNS depression effects by the combination of Methsuximide and Lasmiditan.	Migraine [8A80]	[9]

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Quinoline yellow WS	E00309	24671	Colorant
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sunset yellow FCF	E00255	17730	Colorant
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Methsuximide 300 mg capsule	300 mg	Oral Capsule	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

• [1] Methsuximide FDA Label
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7228).
• [3] Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
• [4] Block of cloned human T-type calcium channels by succinimide antiepileptic drugs. Mol Pharmacol. 2001 Nov;60(5):1121-32.
• [5] The role of S-mephenytoin hydroxylase (CYP2C19) in the metabolism of the antimalarial biguanides. Br J Clin Pharmacol. 1995 Apr;39(4):441-4.
• [6] Belcastro V, Costa C, Striano P "Levetiracetam-associated hyponatremia." Seizure 17 (2008): 389-90. [PMID: 18584781]
• [7] Cerner Multum, Inc. "Australian Product Information.".
• [8] Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
• [9] Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.